During the last session, Clovis Oncology Inc. (NASDAQ:CLVS)’s traded shares were 2.73 million, with the beta value of the company hitting 0.46. At the end of the trading day, the stock’s price was $1.65, reflecting an intraday gain of 3.12% or $0.05. The 52-week high for the CLVS share is $5.24, that puts it down -217.58 from that peak though still a striking 64.85% gain since the share price plummeted to a 52-week low of $0.58. The company’s market capitalization is $244.53M, and the average trade volume was 13.66 million shares over the past three months.
Clovis Oncology Inc. (CLVS) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 3.30. CLVS has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.41.
Clovis Oncology Inc. (NASDAQ:CLVS) trade information
Clovis Oncology Inc. (CLVS) registered a 3.12% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 3.12% in intraday trading to $1.65 this Wednesday, 08/03/22, hitting a weekly high. The stock’s 5-day price performance is -4.07%, and it has moved by -31.54% in 30 days. Based on these gigs, the overall price performance for the year is -66.05%. The short interest in Clovis Oncology Inc. (NASDAQ:CLVS) is 28.58 million shares and it means that shorts have 1.08 day(s) to cover.
The consensus price target of analysts on Wall Street is $3.00, which implies an increase of 45.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3.00 and $3.00 respectively. As a result, CLVS is trading at a discount of -81.82% off the target high and -81.82% off the low.
Clovis Oncology Inc. (CLVS) estimates and forecasts
Statistics show that Clovis Oncology Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Clovis Oncology Inc. (CLVS) shares have gone down -21.05% during the last six months, with a year-to-date growth rate more than the industry average at 26.43% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 32.80% this quarter and then jump 26.80% in the quarter after that. In the rating firms’ projections, revenue will increase 4.10% compared to the previous financial year.
Revenue for the current quarter is expected to be $37.03 million as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to $39.61 million by the end of Sep 2022.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 24.10%. While earnings are projected to return 47.70% in 2022.
Clovis Oncology Inc. is due to release its next quarterly earnings in September. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Clovis Oncology Inc. (NASDAQ:CLVS)’s Major holders
Clovis Oncology Inc. insiders own 1.44% of total outstanding shares while institutional holders control 40.20%, with the float percentage being 40.79%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 205 institutions own stock in it. As of Mar 30, 2022, the company held over 12.35 million shares (or 8.58% of all shares), a total value of $24.94 million in shares.
The next largest institutional holding, with 9.99 million shares, is of Blackrock Inc.’s that is approximately 6.94% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $20.17 million.
Also, the Mutual Funds coming in first place with the largest holdings of Clovis Oncology Inc. (CLVS) shares are Vanguard Total Stock Market Index Fund and Vanguard Explorer Fund, Inc. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 3.82 million shares. This amounts to just over 2.65 percent of the company’s overall shares, with a $7.71 million market value. The same data shows that the other fund manager holds slightly less at 3.02 million, or about 2.10% of the stock, which is worth about $6.03 million.